Alfred Morgenstern Selected Research

Radioimmunotherapy

2/2020	Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer.
1/2018	Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
12/2017	Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model.
3/2017	A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β-Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer.
1/2017	α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
5/2016	Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
4/2016	[Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].
3/2015	α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
1/2015	Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis.
1/2015	Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alfred Morgenstern Research Topics

Disease

70	Neoplasms (Cancer) 05/2022 - 11/2004
31	Prostatic Neoplasms (Prostate Cancer) 10/2022 - 04/2006
10	Carcinoma (Carcinomatosis) 10/2022 - 10/2005
8	Multiple Myeloma 01/2022 - 04/2007
8	Ovarian Neoplasms (Ovarian Cancer) 02/2020 - 03/2006
7	Neoplasm Metastasis (Metastasis) 01/2022 - 12/2009
7	Glioma (Gliomas) 01/2021 - 05/2016
7	Breast Neoplasms (Breast Cancer) 04/2020 - 12/2009
7	Peritoneal Neoplasms 01/2018 - 06/2007
6	Infections 01/2014 - 04/2009
5	Brain Neoplasms (Brain Tumor) 03/2020 - 01/2018
5	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020 - 10/2009
5	Neoplasm Micrometastasis 01/2015 - 12/2006
4	Glioblastoma (Glioblastoma Multiforme) 10/2021 - 01/2018
4	Melanoma (Melanoma, Malignant) 03/2021 - 06/2007
4	Ascites 12/2017 - 01/2008
4	Stomach Neoplasms (Stomach Cancer) 08/2007 - 10/2005
3	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022 - 01/2018
3	Xerostomia 10/2021 - 01/2018
3	Residual Neoplasm 01/2021 - 08/2005
3	Pancreatic Neoplasms (Pancreatic Cancer) 10/2014 - 01/2005
2	Disease Progression 01/2021 - 09/2013
2	Leukemia 01/2020 - 03/2007
2	Body Weight (Weight, Body) 12/2017 - 01/2017
2	Communicable Diseases (Infectious Diseases) 07/2012 - 05/2006
2	Necrosis 04/2012 - 02/2009
2	Cryptococcosis 01/2012 - 04/2009
2	Mycoses (Diseases, Fungus) 11/2009 - 05/2006
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2022
1	Seizures (Absence Seizure) 10/2021
1	Aphasia (Dysphasia) 10/2021
1	Paresis (Hemiparesis) 10/2021
1	Thrombocytopenia (Thrombopenia) 10/2021
1	Hyperthermia 02/2020
1	Inflammation (Inflammations) 01/2019

Drug/Important Bio-Agent (IBA)

27	Radioisotopes (Radionuclides)IBA 05/2022 - 03/2006
23	AntigensIBA 10/2022 - 08/2005
19	Monoclonal AntibodiesIBA 04/2020 - 10/2005
12	Immunoconjugates (Immunoconjugate)IBA 05/2022 - 12/2006
8	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 10/2021 - 03/2016
8	LigandsIBA 10/2021 - 01/2008
8	AntibodiesIBA 03/2021 - 05/2006
7	Peptides (Polypeptides)IBA 12/2018 - 01/2008
6	Substance PIBA 10/2021 - 05/2016
5	Trastuzumab (Herceptin)FDA Link 04/2020 - 03/2006
5	Bismuth-213IBA 01/2015 - 03/2006
4	Actinium-225IBA 05/2022 - 01/2016
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 10/2013
4	Proteins (Proteins, Gene)FDA Link 12/2017 - 06/2007
3	Single-Domain AntibodiesIBA 01/2022 - 04/2020
3	Prostate-Specific Antigen (Semenogelase)IBA 10/2021 - 01/2018
3	Pentetic Acid (DTPA)FDA LinkGeneric 04/2020 - 05/2009
3	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 03/2020 - 04/2017
3	LipidsIBA 01/2019 - 01/2016
3	ErbB Receptors (EGF Receptor)IBA 01/2018 - 10/2009
3	LuciferasesIBA 01/2015 - 10/2009
3	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 02/2009 - 01/2005
2	Lutetium-177IBA 05/2022 - 01/2015
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022 - 01/2014
2	Somatostatin Receptors (Somatostatin Receptor)IBA 12/2021 - 12/2018
2	Therapeutic UsesIBA 03/2021 - 01/2017
2	Chelating AgentsIBA 04/2020 - 05/2016
2	Biological ProductsIBA 03/2020 - 01/2018
2	RadiopharmaceuticalsIBA 03/2020 - 05/2016
2	Pharmaceutical PreparationsIBA 02/2020 - 08/2006
2	Peptide Receptors (Peptide Receptor)IBA 12/2018 - 02/2011
2	Peptide FragmentsIBA 01/2018 - 04/2017
2	substance P (5-11)IBA 01/2018 - 04/2017
2	Carcinoembryonic AntigenIBA 01/2017 - 10/2005
2	Liposomes (Liposome)IBA 01/2017 - 01/2014
2	Neoplasm Antigens (Tumor Antigens)IBA 04/2016 - 01/2015
2	(213)Bi-DTPA-F3IBA 12/2012 - 04/2012
2	Plasminogen Activators (Plasminogen Activator)IBA 02/2009 - 01/2005
2	3-O-(methylthiomethyl)apiitol tetraacetateIBA 02/2009 - 12/2006
2	Urokinase Plasminogen Activator ReceptorsIBA 01/2008 - 01/2005
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2007 - 08/2006
2	Plasminogen InactivatorsIBA 04/2006 - 01/2005
1	Carbonic Anhydrase IXIBA 05/2022
1	InterferonsIBA 01/2022
1	CytokinesIBA 01/2022
1	ParaproteinsIBA 01/2022
1	Interleukin-2 (IL2)IBA 01/2022
1	B7-H1 AntigenIBA 03/2021
1	Immune Checkpoint InhibitorsIBA 03/2021
1	CarbonIBA 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	N-succinimidyl 4-guanidinomethyl-3-iodobenzoateIBA 04/2020
1	AcidsIBA 02/2020

Therapy/Procedure

75	Therapeutics 05/2022 - 11/2004
32	Radioimmunotherapy 02/2020 - 11/2004
17	Castration 10/2022 - 12/2016
10	Radiotherapy 01/2020 - 11/2004
5	Aftercare (After-Treatment) 12/2017 - 08/2006
4	Drug Therapy (Chemotherapy) 09/2019 - 08/2006
2	Precision Medicine 01/2022 - 01/2018
2	Catheters 03/2020 - 05/2016
2	Injections 01/2019 - 08/2005
2	Cytoreduction Surgical Procedures 01/2018 - 01/2015
2	Immunotherapy 01/2015 - 11/2010
2	Electrocoagulation (Electrocautery) 01/2015 - 10/2009